Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form.
• People who have been diagnosed with primary central nervous system (CNS) lymphoma — a type of lymphoma that starts in the brain or spinal cord — confirmed by a tissue test before the study screening.
• People whose doctor has determined they are not suitable for a stem cell transplant, either because they are aged 65 or older, or because they have a health comorbidity score of 3 or higher (a measure of other health conditions — confirm with trial site).
• People whose doctor considers them suitable to receive a treatment regimen based on a chemotherapy drug called high-dose methotrexate.
• People who have already received between 4 and 6 doses of high-dose methotrexate-based treatment for their CNS lymphoma before joining the trial, with no other prior cancer treatments for this condition (steroid use for symptom control may be permitted under certain conditions — confirm with trial site).
• People whose CNS lymphoma has responded to prior high-dose methotrexate treatment, meaning scans show the lymphoma has either completely disappeared or mostly gone.
• People with a functional ability score of 0, 1, or 2 on a standard medical scale — meaning they are fully active or able to carry out light activity (confirm with trial site).
• People of childbearing potential who have a negative pregnancy test within 24 hours before starting the study treatment.

Who may not be able to join:

• People whose CNS lymphoma has spread from a lymphoma elsewhere in the body (secondary CNS lymphoma).
• People whose lymphoma is located only in the eye, only in the fluid around the brain and spinal cord, or whose CNS lymphoma has come back or stopped responding to treatment.
• People with a significant medical condition or abnormal lab results that a doctor considers would make participation too risky.
• People who have had another type of cancer that has not been in remission for at least 2 years.
• People who have previously received CAR T-cell therapy or any other gene therapy that involves editing the human genome.
• People with a current or past diagnosis of HIV.
• People with currently active hepatitis B or hepatitis C infection.
• People with an active autoimmune disease that requires treatment with immune-suppressing medications.
• People who have previously had an allogeneic (donor) stem cell transplant or a solid organ transplant and require immune-suppressing medications as a result.
• Additional criteria set out in the study protocol may also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.